Abstract

Bausch + Lomb Corp. is scheduled to report quarterly results on April 29, 2026 Pre-Market, and our preview highlights a projected revenue of 1.22 billion US dollars with adjusted EPS near 0.06, alongside product clearances and launches that set the stage for operational momentum through the first half of 2026.

Market Forecast

Based on the latest compiled expectations, the market projects Bausch + Lomb Corp.’s current-quarter revenue at approximately 1.22 billion US dollars, representing 5.82% year-over-year growth, with EBIT around 111.70 million US dollars and adjusted EPS near 0.06, implying an estimated year-over-year increase of 115.06%. Forecasted EBIT growth of 9.07% suggests operating leverage from new product introductions; margin forecasts are not formally disclosed for this quarter in the dataset, so we refrain from estimating gross or net margins here. The main commercial engine remains broad-based across devices and consumer health, with expectations for steady sell-through supported by new surgical tools and intraocular lens launches; on a company level, management aims to translate innovation into gradual top-line expansion through 2026. The most promising near-term contribution appears concentrated in surgical and retina devices, where last reported trailing revenue for the broader devices category totaled 1.92 billion US dollars and company-level revenue growth is forecast at 5.82% year-over-year for the current quarter, offering a supportive backdrop for device-led uplift.

Last Quarter Review

In the last reported quarter, Bausch + Lomb Corp. delivered revenue of 1.41 billion US dollars (up 9.77% year over year), a gross profit margin of 62.06%, a GAAP net loss attributable to the parent company of 58.00 million US dollars with a net profit margin of -4.13%, and adjusted EPS of 0.32 (up 28.00% year over year). One key financial highlight was a top-line beat versus compiled expectations, as the company’s 1.41 billion US dollars revenue exceeded the 1.38 billion US dollars consensus by 0.02 billion US dollars. By contribution on the latest available breakdown, devices and OTC medicines remained the largest revenue pools at 1.92 billion and 1.83 billion US dollars, respectively, while total company revenue advanced 9.77% year over year in the last reported period.

Current Quarter Outlook

Core Commercial Engine: Consumer Health and Daily Vision Care

The company’s consumer-facing portfolio in eye care and vision maintenance is set up for steady sell-through, as reflected in the top-line forecast of 1.22 billion US dollars and a 5.82% year-over-year growth profile this quarter. Within the last reported mix, OTC medicines accounted for 1.83 billion US dollars on a trailing basis, underscoring a substantial base of recurring demand that can cushion seasonal variability. Given the magnitude of consumer channels and brand familiarity, modest price and mix actions—combined with targeted promotions—could support unit stability without exerting outsized pressure on gross margin, which last quarter stood at 62.06%. A key watchpoint is promotional cadence, which, if elevated to defend shelf space, can dilute contribution margins even when units hold firm. The projected EBIT of 111.70 million US dollars and implied 9.07% year-over-year growth suggest manageable operating expense intensity despite investment into new product support and marketing. With adjusted EPS guided by consensus to roughly 0.06, we infer a balanced profile: supportive top-line trends and controlled operating costs allowing for incremental earnings growth, though GAAP profitability will continue to depend on non-operating items and below-the-line factors this quarter.

Highest-Potential Growth: Surgical Devices and Retina

Momentum in surgical solutions is a central near-term narrative. Recent clearance in the United States for an advanced dual-port vitrectomy cutter and an adaptive fluidics software update for the company’s surgical system adds functionality aimed at enhancing precision and procedure efficiency. The company also began commercial availability in Europe of preloaded enVista Envy full range of vision intraocular lenses, a meaningful expansion to the surgical catalogue that may support procedure adoption and case mix optimization. On a trailing basis, the broader devices category represented 1.92 billion US dollars in revenue, providing a sizable foundation for incremental gains from new tool deployments. While segment-specific year-over-year growth is not disclosed in the dataset, the company’s aggregate revenue growth is forecast at 5.82% this quarter; given the timing of regulatory clearances and rollouts, surgical devices are positioned to outpace this company-level growth rate through improved utilization and product pull-through. Additionally, positive US clinical trial readouts for an excimer laser–based glaucoma procedure (Elios) achieved predefined endpoints at 24 months, which, although not yet a commercial driver in the US, strengthens the pipeline and the medium-term case for procedure-led revenue expansion. The near-term determinant of uplift will be the pace at which new surgical tools translate into orders and installed-base engagement. From an operational standpoint, adoption curves often depend on training, surgeon preference, and procurement cycles; even so, the combination of new retinal tools and IOL availability in Europe supports a constructive case for sequential device revenue contribution. Given the forecasted EBIT growth of 9.07%, incremental gross profit from higher-value devices could provide modest mix benefits as the quarter progresses.

Key Stock Price Drivers This Quarter

The stock’s reaction is likely to center on the revenue trajectory relative to the 1.22 billion US dollars expectation and delivery versus the 5.82% year-over-year growth bogey. EPS near 0.06 implies consensus sees reinvestment balanced with operating leverage; exceeding this mark would likely require either stronger mix in surgical and retina or tighter-than-expected expense control. Conversely, any shortfall in consumer channel sell-through, or slower-than-anticipated uptake of recently cleared/introduced surgical devices, could dampen implied operating leverage despite a supportive product cadence. News flow around the surgical suite—particularly early indicators of order momentum following US clearance of the retinal tools and European IOL deployments—will be scrutinized for evidence of conversion into revenue. Furthermore, investors will parse commentary around the pipeline and the timeline for broader commercialization of glaucoma solutions in the US, as that topic shapes medium-term growth narratives and capital allocation. Finally, qualitative guidance relative to full-year 2026 revenue aspirations (recently referenced at a range of 5.38 billion to 5.48 billion US dollars) will provide context on the durability of high-single-digit growth aims and the cadence of operating expense investment across product launches.

Analyst Opinions

Bullish-to-bearish ratio in the recent period stands at 2:0 on the institutional calls we tracked, pointing to a majority bullish stance. On January 27, 2026, RBC Capital Markets increased its price target to 21 US dollars while maintaining an Outperform rating, citing a constructive view anchored in product catalysts and execution into 2026. On March 3, 2026, Morgan Stanley reiterated a Buy rating with a 21 US dollars price target, reinforcing confidence that product clearances and rollouts can support revenue and earnings expansion over the coming quarters. The bullish camp emphasizes two pillars. First, the current-quarter setup features a projected revenue of 1.22 billion US dollars and 5.82% year-over-year expansion, a pace that aligns with a path toward the recently referenced 2026 revenue range of 5.38 billion to 5.48 billion US dollars. Second, the approval and commercialization milestones in surgical and retina—US clearance for a high-speed dual-port vitrectomy cutter with adaptive fluidics and European availability for preloaded enVista Envy intraocular lenses—represent tangible catalysts that can enhance product mix and drive operating leverage, consistent with the 9.07% EBIT growth outlook this quarter. From a valuation and expectations perspective, the bullish narrative highlights improving adjusted earnings power, with consensus pointing to an EPS near 0.06 this quarter, up 115.06% year over year on an adjusted basis. This stance sees upside if revenue conversion from surgical introductions accelerates and if consumer health volumes remain resilient enough to sustain gross margin near the last reported 62.06%. Supportive ratings from global banks, alongside a previously cited average rating of overweight and a mean price target in the high-teens to low-20s range, frame a constructive skew into the print, with upside sensitivity to device-led beat-and-raise dynamics.